Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502253-34-00

Enrollment

Registered

2023-05-02

Start date

2023-09-11

Completion date

Unknown

Last updated

2023-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Brief summary

Disease Control Rate (DCR)

Detailed description

Progression-Free Survival (PFS), Overall Survival (OS), Overall Response Rate (ORR), Response Duration (DoR)

Interventions

DRUGCISPLATINO SANDOZ

DRUGPemetrexed Mylan 25 mg/ml concentrato per soluzione per infusione

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGPaclitaxel Mylan Generics 6 mg/ml concentrato per soluzione per infusione

DRUGCARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease Control Rate (DCR)	—

Secondary

Measure	Time frame
Progression-Free Survival (PFS), Overall Survival (OS), Overall Response Rate (ORR), Response Duration (DoR)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026